Abstract #1841

Fluorine-19 MR Characterisation of Siponimod as MR Theranostic Approach in the Treatment of Multiple Sclerosis

Christian Prinz¹, Fatima Sherazi¹, Ludger Starke¹, Paula Ramos Delgado¹, Andre Kuehne², Thoralf Niendorf^1,2,3, and Sonia Waiczies¹

¹Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ²MRI TOOLS GmbH, Berlin, Germany, ³Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Siponimod is a trifluorinated anti-inflammatory drug indicated for Multiple Sclerosis that could be potentially tracked in pharmacokinetic studies by fluorine-19 (¹⁹F) MR techniques in order to support therapeutic monitoring. In this study, we investigated the ¹⁹F MR properties of siponimod and its dependency on environmental factors. We found a temperature dependence of the relaxation times T₁ and T₂ and identified a T₂-drop in the presence of human serum. We identified UTE as SNR-efficient MR pulse sequence to study siponimod physiologically and show the potential of tailoring MR methods in the future to individual patient therapeutic needs.

This abstract and the presentation materials are available to members only; a login is required.

Join Here